ProCE Banner Activity

Improving Empiric Antibiotic Regimens for HABP/VABP in the ICU

Clinical Thought
Learn the answers to commonly asked questions about empiric antibiotic selection for HABP/VABP in the ICU.

Released: November 18, 2022

Expiration: November 17, 2023

Share

Faculty

Marion Elligsen

Marion Elligsen, BScPhm, MSc, RPh, ACPR

Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Keith S. Kaye

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Andrew Shorr

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

Marion Elligsen, BScPhm, MSc, RPh, ACPR

Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Marion Elligsen, BScPhm, MSc, RPh, ACPR, has no relevant financial relationships to disclose.

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH: consultant/advisor/speaker: Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx, ContraFect, Cubist, Entasis, GlaxoSmithKline, Integrated Operations, Melinta, Merck, MicuRx, Nabriva, NS Nanotech, Pratek, Qpex, Shionogi, Spero, Utility, Venatorx, Xellia.

Andrew Shorr, MD, MPH, MBA

Director, Pulmonary and Critical Care Medicine
Washington, DC

Andrew Shorr, MD, MPH, MBA: consultant/advisor/speaker: Merck, Pfizer, Shionogi.